FORTITUDE-101 Study Updates 2025: Bemarituzumab Plus mFOLFOX6 in FGFR2b-Positive Gastric and GEJ Cancer - OncoDaily FORTITUDE-101 Study shows that Bemarituzumab Plus mFOLFOX6 improves OS in patients with FGFR2b-Positive Gastric and GEJ Cancer.

FORTITUDE-101 Study Updates 2025: Bemarituzumab Plus mFOLFOX6 in FGFR2b-Positive Gastric and GEJ Cancer

oncodaily.com/oncolibrary/...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #FORTITUDE101 #Bemarituzumab #mFOLFOX6 #GEJCancer #GastricCancer